Patisiran updates from Alnylam | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34733 of 34746  at  10/31/2019 9:42:21 AM  by

The Rooster


Patisiran updates from Alnylam

 Alnylam reported the following patisiran updates this morning:
 
 

Commercial Performance in Third Quarter 2019

  • Achieved global net product revenues for the third quarter of 2019 of $46.1 million for ONPATTRO.
  • Attained over 600 patients worldwide on commercial ONPATTRO treatment since launch.
  • Continued global expansion with receipt of regulatory approval for ONPATTRO in Switzerland, and initiation of commercial launches in Japan and Canada.
  • Continued progress with market access efforts across the CEMEA region (Canada, Europe, Middle East, and Africa).
    • Following favorable ratings from health technology assessment agencies, achieved reimbursement approvals in the United Kingdom, Belgium, and Germany.
  • Received recognition for ONPATTRO as an innovative biotechnology medicine through award of the prestigious Prix Galien in The Netherlands and Italy and nominations for the Prix Galien in additional countries, including France, Germany, and the U.S.

Late Stage R&D Highlights

  • Advanced patisiran (the non-proprietary name for ONPATTRO), an intravenously administered investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 266
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...